Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Extension Study of AMX0035 in Patients With ALS

Trial Profile

Open Label Extension Study of AMX0035 in Patients With ALS

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium phenylbutyrate/tauroursodeoxycholic acid (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Acronyms CENTAUR-OLE
  • Sponsors Amylyx Pharmaceuticals
  • Most Recent Events

    • 09 Apr 2018 New trial record
    • 04 Apr 2018 According to an Amylyx Pharmaceuticals media release, Sabrina Paganoni, physician at the Massachusetts General Hospital and Spaulding Rehabilitation Hospital is the principal investigator for this study.
    • 04 Apr 2018 According to an Amylyx Pharmaceuticals media release, first patients to complete the CENTAUR phase II clinical trial have been elected to continue treatment in this extension study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top